Menu

Experience

Kay Chandler

    • Horizon Therapeutics to Be Acquired by Amgen for Approximately $28 Billion 


    • Biotech Company ViaCyte to Be Acquired by Vertex Pharmaceuticals 


    • Bristol Myers Squibb to Acquire Turning Point Therapeutics for $4.1 Billion 


    • Nykode Therapeutics Enters Collaboration Agreement with Regeneron 


    • Neurocrine Biosciences Enters Collaboration Agreement with Sosei Heptares 


    • Vividion Therapeutics Agrees to Sell to Bayer for up to $2 Billion 


    • Horizon Therapeutics to Acquire Viela Bio 


    • Artiva: $78 Million Series A Financing 


    • Neurocrine Partners With Takeda to Address Psychiatric Disorders 


    • Horizon Pharma Buys River Vision for $145 Million and Unspecified Earn-Out 


    • Horizon Pharma Acquisition of Crealta Holdings for $510 Million 


    • Auspex Pharma $3.5 billion sale to Teva Pharma 


    • Horizon Pharma Completes $400 Million Exchangeable Senior Notes Offering 


    • Ambit Biosciences to be Acquired by Daiichi Sankyo for $410 Million 


    • Horizon Pharma Acquires Vidara Therapeutics and Enters Five-Year $300 Million Term Loan Facility 


    • Horizon Pharma $660 Million Acquisition of Vidara Therapeutics 


    • Horizon Pharma Acquires Vidara Therapeutics and Enters Five-Year $300 Million Term Loan Facility